CN107531667A - 1‑((2R,4R)‑2‑(1H‑苯并[d]咪唑‑2‑基)‑1‑甲基哌啶‑4‑基)‑3‑(4‑氰基苯基)脲马来酸盐的晶形 - Google Patents

1‑((2R,4R)‑2‑(1H‑苯并[d]咪唑‑2‑基)‑1‑甲基哌啶‑4‑基)‑3‑(4‑氰基苯基)脲马来酸盐的晶形 Download PDF

Info

Publication number
CN107531667A
CN107531667A CN201680023699.0A CN201680023699A CN107531667A CN 107531667 A CN107531667 A CN 107531667A CN 201680023699 A CN201680023699 A CN 201680023699A CN 107531667 A CN107531667 A CN 107531667A
Authority
CN
China
Prior art keywords
ppm
values
following
crystalline form
solid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680023699.0A
Other languages
English (en)
Chinese (zh)
Inventor
E·C·汉森
C·S·西德克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55806563&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN107531667(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of CN107531667A publication Critical patent/CN107531667A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201680023699.0A 2015-04-24 2016-04-13 1‑((2R,4R)‑2‑(1H‑苯并[d]咪唑‑2‑基)‑1‑甲基哌啶‑4‑基)‑3‑(4‑氰基苯基)脲马来酸盐的晶形 Pending CN107531667A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562152108P 2015-04-24 2015-04-24
US62/152,108 2015-04-24
PCT/IB2016/052107 WO2016170451A1 (en) 2015-04-24 2016-04-13 Crystalline forms of 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate

Publications (1)

Publication Number Publication Date
CN107531667A true CN107531667A (zh) 2018-01-02

Family

ID=55806563

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680023699.0A Pending CN107531667A (zh) 2015-04-24 2016-04-13 1‑((2R,4R)‑2‑(1H‑苯并[d]咪唑‑2‑基)‑1‑甲基哌啶‑4‑基)‑3‑(4‑氰基苯基)脲马来酸盐的晶形

Country Status (24)

Country Link
US (4) US10414748B2 (enExample)
EP (2) EP3666768B1 (enExample)
JP (1) JP6345728B2 (enExample)
KR (2) KR20190038677A (enExample)
CN (1) CN107531667A (enExample)
AR (1) AR104391A1 (enExample)
AU (1) AU2016251940C1 (enExample)
BR (1) BR112017021075B1 (enExample)
CA (2) CA2983387C (enExample)
CY (2) CY1124056T1 (enExample)
DK (2) DK3666768T3 (enExample)
ES (2) ES2923593T3 (enExample)
HK (1) HK1243416A1 (enExample)
HU (2) HUE048664T2 (enExample)
IL (1) IL255224B (enExample)
MX (1) MX375384B (enExample)
PL (2) PL3286176T3 (enExample)
PT (2) PT3666768T (enExample)
RU (1) RU2717564C2 (enExample)
SG (1) SG11201707863QA (enExample)
SI (2) SI3286176T1 (enExample)
TW (1) TWI646093B (enExample)
WO (1) WO2016170451A1 (enExample)
ZA (1) ZA201706391B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114668849A (zh) * 2021-12-31 2022-06-28 中国人民解放军军事科学院军事医学研究院 Shh通路调控生物节律及其相关应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2983387C (en) 2015-04-24 2022-08-16 Pfizer Inc. Crystalline forms of 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate
US20230107634A1 (en) * 2020-01-28 2023-04-06 Teva Pharmaceuticals International Gmbh Processes for the preparation of glasdegib and salt thereof and solid state forms of glasdegib maleate and process for preparation thereof
EP4126237B1 (en) 2020-03-26 2024-04-10 LEK Pharmaceuticals d.d. Dimaleate form of 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea
WO2023002362A1 (en) 2021-07-22 2023-01-26 Pfizer Inc. Treatment of hematological malignancy
WO2023017541A1 (en) * 2021-08-12 2023-02-16 Msn Laboratories Private Limited, R&D Center Improved process for the preparation of 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-methyl piperidin-4-yl)-3-(4-cyanophenyl)urea maleate

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101687841A (zh) * 2007-06-29 2010-03-31 辉瑞大药厂 苯并咪唑衍生物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0325956D0 (en) * 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
WO2008001575A1 (fr) 2006-06-28 2008-01-03 Nikon Corporation Dispositif de localisation, dispositif de mise au point automatique et appareil photographique
CA2983387C (en) 2015-04-24 2022-08-16 Pfizer Inc. Crystalline forms of 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101687841A (zh) * 2007-06-29 2010-03-31 辉瑞大药厂 苯并咪唑衍生物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MICHAEL J. MUNCHHOF ET AL.: "Discovery of PF-04449913, a Potent and Orally Bioavailable Inhibitor of Smoothened", 《ACS MEDICINAL CHEMISTRY LETTERS》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114668849A (zh) * 2021-12-31 2022-06-28 中国人民解放军军事科学院军事医学研究院 Shh通路调控生物节律及其相关应用
CN114668849B (zh) * 2021-12-31 2024-01-23 中国人民解放军军事科学院军事医学研究院 Shh通路调控生物节律及其相关应用

Also Published As

Publication number Publication date
RU2017137269A3 (enExample) 2019-09-13
AU2016251940A1 (en) 2017-10-12
AU2016251940B2 (en) 2018-08-30
ES2774053T3 (es) 2020-07-16
SG11201707863QA (en) 2017-11-29
US20190382368A1 (en) 2019-12-19
RU2717564C2 (ru) 2020-03-24
HK1243416A1 (zh) 2018-07-13
EP3666768A1 (en) 2020-06-17
US20180086731A1 (en) 2018-03-29
PT3286176T (pt) 2020-02-24
MX2017013645A (es) 2018-03-08
CA2983387C (en) 2022-08-16
TWI646093B (zh) 2019-01-01
IL255224B (en) 2021-01-31
ES2923593T3 (es) 2022-09-28
MX375384B (es) 2025-03-06
JP6345728B2 (ja) 2018-06-20
US10414748B2 (en) 2019-09-17
CY1125333T1 (el) 2025-03-28
BR112017021075B1 (pt) 2021-08-03
HUE059506T2 (hu) 2022-11-28
AU2016251940C1 (en) 2019-04-11
DK3666768T3 (da) 2022-06-27
US11891372B2 (en) 2024-02-06
ZA201706391B (en) 2020-12-23
SI3666768T1 (sl) 2022-09-30
SI3286176T1 (sl) 2020-04-30
US11891373B2 (en) 2024-02-06
WO2016170451A1 (en) 2016-10-27
AR104391A1 (es) 2017-07-19
TW201702238A (zh) 2017-01-16
KR20190038677A (ko) 2019-04-08
HUE048664T2 (hu) 2020-07-28
CA2927736A1 (en) 2016-10-24
EP3286176B1 (en) 2020-01-15
CA2983387A1 (en) 2016-10-27
JP2016204373A (ja) 2016-12-08
NZ735719A (en) 2020-11-27
PL3286176T3 (pl) 2020-11-30
CY1124056T1 (el) 2022-03-24
PL3666768T3 (pl) 2022-09-19
US20220024893A1 (en) 2022-01-27
US11168066B2 (en) 2021-11-09
KR102078444B1 (ko) 2020-02-17
EP3666768B1 (en) 2022-06-15
PT3666768T (pt) 2022-07-22
EP3286176A1 (en) 2018-02-28
US20220024894A1 (en) 2022-01-27
IL255224A0 (en) 2017-12-31
DK3286176T3 (da) 2020-03-02
BR112017021075A2 (pt) 2018-07-03
RU2017137269A (ru) 2019-05-24
KR20170129245A (ko) 2017-11-24

Similar Documents

Publication Publication Date Title
CN107531667A (zh) 1‑((2R,4R)‑2‑(1H‑苯并[d]咪唑‑2‑基)‑1‑甲基哌啶‑4‑基)‑3‑(4‑氰基苯基)脲马来酸盐的晶形
RU2497820C2 (ru) Кристаллические формы и две сольватные формы солей молочной кислоты 4-амино-5-фтор-3-[5-(4-метилпиперазин-1-ил)-1 - н-бензимидазол-2-ил]хинолин-2(1н)она
JP6609065B2 (ja) １−（５−（２，４−ジフルオロフェニル）−１−（（３−フルオロフェニル）スルホニル）−４−メトキシ−１ｈ−ピロール−３−イル）−ｎ−メチルメタンアミンの新規な酸付加塩
JP4733037B2 (ja) ３−（４−アミノ−１−オキソ−１，３ジヒドロ−イソインドール−２−イル）−ピペリジン−２，６−ジオンの多形相
JP2020125307A (ja) オメカムチブメカルビルの塩及び塩を調製するプロセス
US10689380B1 (en) Crystalline forms of valbenazine ditosylate
JPWO2014017515A1 (ja) ４−［５−（ピリジン−４−イル）−１ｈ−１，２，４−トリアゾール−３−イル］ピリジン−２−カルボニトリルの結晶多形およびその製造方法
EP4352051A1 (en) New solid forms of (3r)-n-[2-cyano-4-fluoro-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]-3-fluoro-pyrrolidine-1-sulfonamide
NZ735719B2 (en) Crystalline forms of 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate
TW202527943A (zh) 2-(4-(2-(7,8-二甲基-[1,2,4]三唑[1,5-a]吡啶-6-基)-3-異丙基-1h-吲哚-5-基)哌啶-1-基)乙醯胺鹽及其結晶形式
TW202440125A (zh) 水解磷脂酸合成脢抑制劑化合物的新穎晶形
KR20250024987A (ko) 4-[(5-클로로피리딘-2-일)메톡시]-1-[3-(프로판-2-일)-1H,2H,3H,4H,5H-[1,4]디아제피노[1,7-a]인돌-9-일]-1,2-디하이드로피리딘-2-온의결정질 형태 및 이의 염, 이의 제조 방법 및 용도
HK40063558A (en) Pharmaceutical salts of benzothiazol compounds, polymorphs and methods for preparation thereof
CN113631554A (zh) 苯并噻唑化合物的药用盐、多晶型物及其制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1243416

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20180102

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1243416

Country of ref document: HK